HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.

Abstract
The majority of ovarian cancer patients acquire resistance to standard platinum chemotherapy and novel therapies to reduce tumor burden and ascites accumulation are needed. Pregnancy-associated plasma protein-A (PAPP-A) plays a key role in promoting insulin-like growth factor (IGF) pathway activity, which directly correlates to ovarian cancer cell transformation, growth, and invasiveness. Herein, we evaluate PAPP-A expression in tumors and ascites of women with ovarian cancer, and determine the antitumor efficacy of a neutralizing monoclonal PAPP-A antibody (mAb-PA) in ovarian cancer using primary patient ovarian tumorgrafts ("Ovatars"). PAPP-A mRNA expression in patient ovarian tumors correlated with poor outcome and was validated as a prognostic surrogate in Ovatar tumors. Following confirmation of mAb-PA bioavailability and target efficacy in vivo, the antitumor efficacy of mAb-PA in multiple Ovatar tumor models was examined and the response was found to depend on PAPP-A expression. Strikingly, the addition of mAb-PA to standard platinum chemotherapy effectively sensitized platinum-resistant Ovatar tumors. PAPP-A protein in ascites was also assessed in a large cohort of patients and very high levels were evident across the entire sample set. Therefore, we evaluated targeted PAPP-A inhibition as a novel approach to managing ovarian ascites, and found that mAb-PA inhibited the development, attenuated the progression, and induced the regression of Ovatar ascites. Together, these data indicate PAPP-A as a potential palliative and adjunct therapeutic target for women with ovarian cancer.
AuthorsMarc A Becker, Paul Haluska Jr, Laurie K Bale, Claus Oxvig, Cheryl A Conover
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 14 Issue 4 Pg. 973-81 (Apr 2015) ISSN: 1538-8514 [Electronic] United States
PMID25695953 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright©2015 American Association for Cancer Research.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antineoplastic Agents
  • Carboplatin
  • Pregnancy-Associated Plasma Protein-A
  • Paclitaxel
Topics
  • Animals
  • Antibodies, Monoclonal (administration & dosage, pharmacology)
  • Antibodies, Neutralizing (administration & dosage, pharmacology)
  • Antineoplastic Agents (administration & dosage, pharmacology)
  • Ascites (pathology)
  • Carboplatin (administration & dosage, pharmacology)
  • Cell Line, Tumor
  • Disease Models, Animal
  • Female
  • Gene Expression
  • Humans
  • Immunohistochemistry
  • Mice
  • Ovarian Neoplasms (drug therapy, genetics, metabolism, mortality, pathology)
  • Paclitaxel (administration & dosage, pharmacology)
  • Pregnancy-Associated Plasma Protein-A (antagonists & inhibitors, genetics, metabolism)
  • Prognosis
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: